Human a proliferation inducing ligand(APRIL)ELISA Kit

Code CSB-E15012h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name tumor necrosis factor (ligand) superfamily, member 13
Alternative Names A proliferation inducing ligand ELISA Kit; A proliferation-inducing ligand ELISA Kit; APRIL ELISA Kit; CD256 ELISA Kit; TALL-2 ELISA Kit; TALL2 ELISA Kit; TNF related death ligand ELISA Kit; TNF- and APOL-related leukocyte expressed ligand 2 ELISA Kit; TNF-related death ligand 1 ELISA Kit; TNF13_HUMAN ELISA Kit; TNFSF13 ELISA Kit; TRDL-1 ELISA Kit; TRDL1 ELISA Kit; Tumor necrosis factor (ligand) superfamily; member 13 ELISA Kit; Tumor necrosis factor ligand superfamily member 13 ELISA Kit; Tumor necrosis factor like protein ZTNF2 ELISA Kit; Tumor necrosis factor related death ligand 1 ELISA Kit; UNQ383/PRO715 ELISA Kit; ZTNF2 ELISA Kit
Abbreviation TNFSF13
Uniprot No. O75888
Species Homo sapiens (Human)
Sample Types serum, plasma, urine
Detection Range 0.78 ng/mL-50 ng/mL
Sensitivity 0.195 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human APRIL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 94  
Range % 90-98  
1:2 Average % 92  
Range % 88-97  
1:4 Average % 86  
Range % 82-90  
1:8 Average % 98  
Range % 94-102  
The recovery of human APRIL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 104 100-108  
EDTA plasma (n=4) 97 92-101  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
50 2.285 2.352 2.319 2.179  
25 1.605 1.565 1.585 1.445  
12.5 1.053 1.104 1.079 0.939  
6.25 0.656 0.679 0.668 0.528  
3.12 0.411 0.396 0.404 0.264  
1.56 0.298 0.318 0.308 0.168  
0.78 0.212 0.209 0.211 0.071  
0 0.143 0.137 0.140    
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes.
Gene References into Functions
  1. TNFSF13, SPATC1L, SLC22A25 and SALL4 may thus be novel susceptibility loci for atrial fibrillation in the Japanese population PMID: 28849223
  2. The results suggest that increased levels of BAFF and APRIL produced in the central nervous system may influence the development of anti-neutrophil cytoplasmic antibody-hypertrophic pachymeningitis. PMID: 28847534
  3. The genetic variations and gene expression level of TNFSF13 are associated with the susceptibility and severity of IgA nephropathy in a Han Chinese population. PMID: 28636766
  4. APRIL levels are associated with disease activity in human chronic graft-versus-host disease. PMID: 26992945
  5. APRIL but not BLyS promotes IL-10 production by CpG-activated B cells and enhances the regulatory role of B cells on T cells. PMID: 27372914
  6. BCMA has other contributors for ligands binding except DxL motif. The affinity of BCMA for APRIL higher than for BAFF may be caused by the segment outside of the conservative DxL motif. Moreover, the exposition of new binding modes of BCMA2 interacting with APRIL may establish the foundation of designing novel drugs in the future PMID: 28260502
  7. APRIL transgenic mice infected by Helicobacter species may represent a novel animal model of gastric lymphomagenesis. PMID: 28460208
  8. ApoE-/-APRIL-Tg mice have increased oxLDL-specific serum IgM levels, potentially mediated via an increase in B1a lymphocytes PMID: 27820817
  9. Results showed that chemokine-mediated recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression. PMID: 27923834
  10. This study showed that both BAFF and APRIL levels were increased in CSF of patients with anti-NMDAR encephalitis. PMID: 28284352
  11. The results demonstrated that rs11552708 of the APRIL gene is not associated with Systemic lupus erythematosus (SLE) susceptibility in Iranian children. Likewise, these findings suggest that APRIL antagonist could be a potential therapeutic target to control SLE in children. PMID: 27878683
  12. New molecular mechanisms of in vivo Multiple Myeloma (MM) growth and immunosuppression critically dependent on BCMA and APRIL in the Bone marrow microenvironment, further supporting targeting this prominent pathway in MM. PMID: 27127303
  13. Urinary APRIL (uAPRIL) and BAFF (uBAFF) levels were raised significantly in AN. PMID: 27804111
  14. High expression of APRIL is associated with hepatocellular carcinoma. PMID: 28035399
  15. Data did not detect any significant association with SNPs of APRIL, SPATA8, PDGFRA, and POLB with Systemic Lupus Erythematosus in Chinese Han Population. PMID: 27569236
  16. Recombinant human APRIL (rhAPRIL) could rescue HCC cell proliferation inhibited by miR-383. PMID: 26385772
  17. high expression of APRIL in clear cell renal cell carcinoma was correlated with high Fuhrman nuclear grade, high pathologic stage, and poor overall and cancer-specific survival of the patients PMID: 26296917
  18. TNFSF13 and FDX1 have potential roles in IgAN in the Han Chinese population. This information may be useful in the development of early prognostics for IgAN. PMID: 26431901
  19. Did not find any positive association between TNFSF13 SNPs and the risk of IgA nephropathy after adjustment for age and sex, but did find a significant and strong correlation with relevant clinical pathological parameters. PMID: 26370181
  20. plasma level elevated in IgA nephropathy PMID: 26986150
  21. results indicate that analysis of serum concentrations of BAFF and APRIL potentially represents a useful tool for the assessment of AIHA disease activity and progression. PMID: 26243624
  22. Abnormal levels of BAFF/APRIL in pediatric acute lymphoblastic leukemia suggest that BAFF/APRIL are associated with the development and progression of this disease in children PMID: 26950089
  23. SNPs rs9514828 (BAFF), rs3803800 (APRIL) and rs4985726 (TACI) may be associated with the risk of development of B-cell chronic lymphocytic leukemia in a Polish population. PMID: 26268376
  24. Data show decrease of serum APRIL levels in diabetic patients with Type-1 Diabetes or Type-2 Diabetes suggesting suggest that APRIL can be considered as a potential modulating cytokine in the inflammatory process of diabetes. PMID: 26469782
  25. Surface APRIL is elevated in circulating myeloid cells in patients with rheumatoid arthritis, where it is highly correlated with disease activity. PMID: 25729037
  26. elevated serum levels in patients with Behcet's disease PMID: 25759827
  27. the elevated presence of APRIL and BLyS in B cell-rich areas of chronically inflamed gingiva suggests that these cytokines may contribute to bone loss by promoting the survival and persistence of RANKL-expressing B cells/plasma cells. PMID: 26150532
  28. Results show that APRIL was significantly up-regulated in gastric cancer and high levels of APRIL correlated with resistance to cisplatin through the activation of the canonical NF-kappaB pathway. PMID: 25612651
  29. APRIL could be a potential diagnosed marker to distinguish glottic malignant disease from glottic benign lesion, and it may play an important role in the development of glottic malignant disease. PMID: 24276470
  30. APRIL expression is correlated with malignant gastrointestinal stromal tumours phenotypes and it may serve as an unfavourable prognostic marker in patients with gastrointestinal stromal tumours PMID: 25393252
  31. High APRIL expression is associated with breast cancer. PMID: 25750171
  32. Data suggest that APRIL protein (a proliferation-inducing ligand) could be a potential biomarker for predicting difficult-to-treat cases of lupus nephritis. PMID: 23171638
  33. APRIL is increased in patients with active systemic lupus erythematosus. PMID: 24748505
  34. Enhanced APRIL levels are associated with acute lymphoblastic leukemia. PMID: 25582383
  35. A high APRIL serum level was significantly associated with decreased progression-free survival in follicular lymphoma patients. PMID: 25146008
  36. APRIL may participate in the formation of seropositive rheumatoid arthritis. PMID: 24898359
  37. Our results suggest that an elevated level of BAFF/APRIL drives the maturation of B cells, subsequently leading to IgA2 class switching, and possibly to the development of interstitial lung disease in patients with mixed connective tissue disease. PMID: 24252051
  38. BAFF and APRIL as well as their cognate receptors (BCMA, TACI) correlate with glioma grade. (Meta-analysis) PMID: 24376672
  39. Show a novel method to obtain soluble human APRIL in Escherichia coli using the elastin-like polypeptide and SUMO (ELP-SUMO) tags. PMID: 24412409
  40. The levels of APRIL correlate with the progression of childhood ALL, which may provide certain clues for monitoring ALL clinically. PMID: 23887020
  41. Levels of serum APRIL are useful biomarkers for disease progression and disease activity in multiple myeloma. PMID: 24141333
  42. APRIL depletion induces cell cycle arrest and apoptosis partly through blocking noncanonical TGF-beta1/ERK. PMID: 23867993
  43. Increased serum expression of APRIL correlates with the development of colorectal neoplasms. PMID: 23792260
  44. Although neither serum BAFF nor APRIL correlated with disease activity in the overall population, elevated serum BAFF and reduced APRIL may be markers of renal and CNS disease in systemic lupus erythematosus patients PMID: 23846230
  45. Our findings indicate TNFSF13 is a prognostic factor in non-small cell lung cancer PMID: 24436270
  46. Both APRIL and B-cell-activating factor (BAFF) regulate spinal cord injury-induced autoimmunity through B-cell maturation antigen (BMCA). PMID: 23088438
  47. increased serum levels of BLyS and APRIL in BD patients supports the notion of a critical role for B cell activation factors in BD, particularly in terms of uveitis and disease activity. PMID: 22752534
  48. Using a capture sequencing strategy, we discovered the B-cell relevant genes IRF8, EBF1, and TNFSF13 as novel targets for IGH deregulation. PMID: 23775715
  49. APRIL protein is upregulated in the serum of patients with opsoclonus-myoclonus syndrome. PMID: 23324534
  50. High serum APRIL is associated with multiple myeloma. PMID: 23768867
  51. The levels of serum BAFF and APRIL were raised in patients with anti-glomerular basement membrane disease and might be associated with disease activity and kidney damage. PMID: 23317407
  52. APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. PMID: 23383143
  53. TLR4 expression and the ERK1/2 signaling pathway appear to play only minor roles in APRIL induction in the cells of patients with cancer. PMID: 23010686
  54. Serum APRIL levels inversely correlate with serum IgG4 levels in patients with IgG4-related disease. PMID: 22531553
  55. TNFSF13 may be a susceptibility gene affecting serum IgM levels in Chinese male population. PMID: 23118916
  56. The association between TLR4 activation and APRIL expression in examined leukocytes might have important implications for the immune response of the host exposed to TLR4 ligands such as lipopolysacharides. PMID: 22763977
  57. Rituximab has differential effects on BAFF and APRIL levels in primary Sjogren's syndrome patients PMID: 22851468
  58. Both tumor-derived APRIL and APRIL produced by non-tumor cells is supportive in colorectal tumorigenesis. PMID: 22705846
  59. the effect of APRIL is mediated via BCMA, which does not activate the classical NF-kappaB pathway, whereas it induces a novel signaling pathway, which involves JNK2 phosphorylation, FOXO3A activation, and GADD45 transcription PMID: 23071284
  60. Both alternative splicing and polymorphisms may affect the generation of functional sAPRIL. PMID: 21984075
  61. found that the BAFF/APRIL system was closely related to the Th1 immune response. Our study delineates previously unreported roles of BAFF and APRIL in the development of tuberculosis PMID: 22719887
  62. BAFF and APRIL gene expression in multiple myeloma cells is down-regulated after glucocorticoid and bortezomib treatment. PMID: 22169295
  63. TNFSF13 could be a susceptible gene which was discovered having relationship with serum IgA level, and smoke might be a factor infecting the IgA level. PMID: 22864923
  64. Our results suggest increased BAFF and APRIL serum levels in juvenile idiopathic arthritis patients denoting their possible role in the disease. PMID: 21733733
  65. These data indicate that BAFF, APRIL, and CD40L form a Chronic lymphocytic leukemia -enhancing bidirectional signaling network linking neoplastic B cells with the microvascular stroma. PMID: 22593611
  66. Data show that the combined analysis of BAFF and APRIL serum levels emerged as an independent predictor of disease progression. PMID: 21707303
  67. CD256 can be found in antibody-mediated rejection (ABMR) tissues. PMID: 22783569
  68. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase. PMID: 22059379
  69. High expression of APRIL in systemic lupus erythematosus and rheumatoid arthritis subset may indicate an association between APRIL and lymphoma in these subsets of rheumatic diseases and may reflect a dysregulation of APRIL in these patient groups. PMID: 21724695
  70. There is no difference in serum APRIL among active vasculitis, inactive vasculitis patients and vasculitis patients with infectious complications. PMID: 21293157
  71. FURIN and its substrate cytokines BAFF and APRIL are over expressed in atherosclerotic plaques. PMID: 21889147
  72. Data indicate that BAFF and APRIL can induce inflammatory activation of THP-1 cells through the activation of their receptors (TAC1, BAFF-R, and BCMA) and MAPK, which leads to the subsequent activation of NF-kappaB. PMID: 21505913
  73. BAFF/APRIL inhibition with TACI-Ig induces a significant decrease in the survival of transgenic B cells in the periphery in chimeric mice. PMID: 22102726
  74. APRIL levels in cerebrospinal fluid were increased in neuropsychiatric systemic lupus erythematosus as compared with those in other neurological diseases. There was a positive correlation between cerebrospinal fluid APRIL levels and fatigue. PMID: 21585290
  75. The expression of these BAFF, APRIL and TWEAK was analyzed in atopic eczema, seborrheic eczema (SE) and healthy controls (HC). PMID: 21765951
  76. APRIL production, both in the human and mouse systems, peaks in myeloid precursor cells, before dropping in fully mature granulocytes. PMID: 21642598
  77. APRIL protein produced by AML cells probably plays an important role in abnormal proliferation and drug-resistance of AML cells. PMID: 21176341
  78. This is the first study, presenting together the TNFSF members APRIL, BAFF, TWEAK and their receptors in different areas of normal renal tissue and renal cell carcinoma. PMID: 21483105
  79. First evidence for an involvement of APRIL in gastric MALT lymphoma development in Helicobacter pylori-infected patients. PMID: 21527528
  80. Our preliminary results suggest increased serum APRIL levels in systemic sclerosis patients, particularly in those associated with myositis and hypergammaglobinemia PMID: 20599414
  81. This is the first study, which details local expression of APRIL and BLyS in glomeruli and tubulointerstitium of human proliferative lupus nephritis. PMID: 20890272
  82. Data show that predominant APRIL-producing cells in the BM microenvironment were not MM cells but were cells of myeloid origin. PMID: 20709908
  83. Production of APRIL is increased in systemic sclerosis peripheral blood mononuclear cells and is associated with the presence of anti-topo I antibodies and more severe disease PMID: 20810514
  84. inverse correlation between BAFF and APRIL in Kawasaki disease is reversed by IVIG treatment PMID: 20945608
  85. membrane form can generate immunomodulatory signals in macrophages PMID: 20518823
  86. A novel immunoassay demonstrated that native BLyS/APRIL heterotrimers, as well as BLyS and APRIL homotrimers, are elevated in patients with autoimmune diseases. PMID: 20302641
  87. APRIL may promote the development of colorectal carcinoma. PMID: 18423122
  88. APRIL is over expressed in untreated active immune thrombocytopenia patients and might be a pathogenic factor of this disorder. PMID: 19824872
  89. The levels of APRIL, BlyS and receptors as TACI, BCMA and BAFF-R in peripheral blood mononuclear cells of cryptococcal meningitis patients and its clinical significance, was investigated. PMID: 19909733
  90. increased plasma levels in patients with coronary artery disease PMID: 19806256
  91. APRIL can serve as a homeostatic down modulator of B-lymphocyte hyperactivity in systemic lupus erythematosus. PMID: 20116334
  92. Over-expression of BLyS/April may be one of factors contributed to the immunological dysfunction in acute idiopathic thrombocytopenic purpura. PMID: 19175985
  93. Low levels of APRIL play an essential role in cellular senescence via a heparan sulfate proteoglycan-dependent signaling pathway in a colon carcinoma cell line. PMID: 19466596
  94. changes in serum APRIL levels were not significant among primary biliary cirrhosis patients, healthy controls and HCV-infected patients PMID: 19840904
  95. results suggest that Gln187 may be a crucial amino acid in APRIL-mediated tumor cell proliferation via the MEK-ERK signaling pathway and that the sAPRIL mutants may serve as novel potential antagonists of APRIL for the therapy of APRIL-associated cancers. PMID: 19997650
  96. The elevated expression level of APRIL mRNA in sputum of NSCLC suggested that APRIL mRNA may serve as an effective and convenient diagnostic biomarker for NSCLC. PMID: 19842833
  97. APRIL is a novel chemo-resistance biomarker with independent predictive impact in 5FU-treated colorectal cancer patients PMID: 20003335
  98. Plasma cells (PCs) accumulate in synovial zones rich in secreted APRIL, consistent with a pro-survival role of APRIL for PCs in rheumatoid arthritis PMID: 19788740
  99. APRIL is involved in the induction and/or maintenance of T and B cell response. PMID: 12070306
  100. When coexpressed with BLYS, APRIL forms active heterotrimeric molecules that circulate in the serum of patients with systemic immune-based rheumatic diseases. PMID: 12370363

Show More

Hide All

Subcellular Location Secreted
Protein Families Tumor necrosis factor family
Tissue Specificity Expressed at high levels in transformed cell lines, cancers of colon, thyroid, lymphoid tissues and specifically expressed in monocytes and macrophages.
Database Links

HGNC: 11928

OMIM: 604472

KEGG: hsa:8741

STRING: 9606.ENSP00000343505

UniGene: Hs.54673

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1